Pink SheetThe US Food and Drug Administration’s July advisory committee schedule includes a curious mix of vaccine safety reviews and the potentially triumphant return of a pulled multiple myeloma drug, in addi
ScripSanofi’s plans for rilzabrutinib continue apace with positive mid-stage data in IgG4-related disease ahead of a potential US approval in the summer for the potential ‘pipeline-in-a-product’ in immune
ScripSpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round f
ScripRiding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com